Indivior Share Price | |
---|---|
Price | 1,406.00 |
Bid | 1,417.00 |
Ask | 1,419.00 |
Change | -32.00 (-2.23%) |
Volume | 232,008 |
Open | 1,432.00 |
High | 1,448.00 |
Low | 1,406.00 |
Prev. Close | 1,438.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.21m |
Market Capitalisation | £1.90b |
Market Size | 500 |
52 Week High | 1,927.00 |
52 Week High Date | 27-Jul-2023 |
52 Week Low | 1,128.00 |
52 Week Low Date | 19-Dec-2023 |
# Trades | 1,034 |
---|---|
Vol. Sold | 152,786 |
Sold Value | £2.17m |
Vol. Bought | 49,262 |
Bought Value | £705.95k |
PE Ratio | 1,790.11135 |
Earnings | 0.785426 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
14-May-24 | 16:50:54 | 1,406.00 | 367 | Sell* | 1,417.00 | 1,419.00 | 5,160 | O Ordinary |
14-May-24 | 16:20:20 | 1,421.00 | 2 | Unknown* | 1,417.00 | 1,419.00 | 28.42 | O Ordinary Delayed publication Was reported as OTC |
14-May-24 | 16:47:01 | 1,422.448 | 7,000 | Buy* | 1,417.00 | 1,419.00 | 99.57k | O Ordinary |
14-May-24 | 16:35:05 | 1,406.00 | 82,906 | Sell* | 1,417.00 | 1,419.00 | 1m | UT Uncrossing Trade |
14-May-24 | 16:29:50 | 1,417.44 | 14 | Sell* | 1,417.00 | 1,419.00 | 198.44 | O Ordinary |
14-May-24 | 16:29:23 | 1,418.56 | 352 | Buy* | 1,417.00 | 1,419.00 | 4,993 | O Ordinary |
14-May-24 | 16:26:57 | 1,417.00 | 18 | Sell* | 1,417.00 | 1,419.00 | 255.06 | A Automatic Execution |
14-May-24 | 15:49:48 | 1,424.00 | 0 | Unknown* | 1,417.00 | 1,419.00 | 0.00 | O Ordinary Delayed publication Was reported as OTC |
14-May-24 | 15:49:48 | 1,424.00 | 0 | Unknown* | 1,417.00 | 1,419.00 | 0.00 | O Ordinary Delayed publication Was reported as OTC |
14-May-24 | 15:49:48 | 1,424.00 | 0 | Unknown* | 1,417.00 | 1,419.00 | 0.00 | O Ordinary Delayed publication Was reported as OTC |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
14-May-24 | 09-May-24 | Buy | Mark Stejbach held the position of Independent Non-Executive Director at the time of this trade.Mark Stejbach | 17.98 | USD | 550 | 13,134 |
18-Mar-24 | 15-Mar-24 | Transfer From | Ryan Preblick held the position of CFO & Executive Director at the time of this trade.Ryan Preblick | 0.00 | 3,920 | 229,089 | |
18-Mar-24 | 18-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,617.00 | GBX | 10,549 | 335,935 |
18-Mar-24 | 15-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,644.00 | GBX | 15,444 | 335,935 |
18-Mar-24 | 14-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,630.00 | GBX | 91,204 | 335,935 |
Indivior is working to change patients lives by developing medicines to treat addiction and serious mental illnesses.